Cancer prevention or drug promotion? Journalists mishandle the tamoxifen story.
The results of a study on the use of tamoxifen as a preventive treatment for women at high risk for breast cancer have been uncritically hailed and widely mishandled by the U.S. media. Journalists need to take a closer look at the creative manipulation of data, the "scientific method," and the potential drug-company profits associated with this study and the resulting recommendations on tamoxifen use.
Poe
A
A
D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D016265:Conflict of Interest; D004345:Drug Industry; D005260:Female; D006293:Health Promotion; D006801:Humans; D008402:Mass Media; D008875:Middle Aged; D011639:Public Opinion; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D016588:Anticarcinogenic Agents; D013629:Tamoxifen